Dementia affects over 55 million people worldwide and Alzheimer’s Disease (AD) accounts for up to 70% of these people. Most Alzheimer’s disease cases are described as late-onset Alzheimer’s disease and occur after the age of 65.
One of the most decisive risk factors in developing Alzheimer’s disease is having two copies of the APOE4 allele, which can result in a 15-fold increase in the risk of developing late-onset Alzheimer’s disease. Around 2–3% of cases are the result of a hereditary condition known as early-onset Alzheimer’s disease, and these are strongly associated with mutations in presenilin-1 (PSEN1), amyloid precursor protein (APP), and presenilin-2 (PSEN2) genes.
We also have iPSCs derived from three patient donors with the ApoE4 genotype for Alzheimer’s, which can be differentiated into any cell type. Please contact us for more information.
Axol Bioscience Sporadic Alzheimer’s Disease Line Collection
Available for customer manufacturing of functional cortical excitatory neurons, cortical inhibitory neurons, microglia, and astrocytes
Axol Bioscience, in partnership with StrataStem, has announced the release of a collection of induced pluripotent stem cell (iPSC) lines derived from patients with sporadic Alzheimer’s Disease (sAD).
This ‘Axol Bioscience Sporadic Alzheimer’s Disease Line Collection’ is available for use in Axol’s custom iPSC-derived cell manufacturing program and represents a significant advancement in the tools available for pre-clinical in vitro model building and drug discovery research.
The collection features 20 fully characterized iPSC lines, including both sAD patients and healthy donor controls, all obtained with full ethical and commercial consent from donors in the Greater Manchester area of the UK. These cell lines are particularly valuable for researchers as they represent age-relevant, gender-mixed samples with comprehensive documentation of ApoE genotypes, medical histories, and family histories.
Learn more in this new guide:
| iPS+A1:G20C | ApoE genotype | CSF Abeta | Family & medical history (Y/N) | Age | Gender | Diagnosis |
| CENSOi004-E | E2/E3 | Not tested | N | 40-50 | M | Not affected at time of donation |
| CENSO-SS-i005-A | E2/E3 | Not tested | Y | 73 | M | Not affected at time of donation |
| CENSO-SS-i007-A | E2/E3 | Not tested | Y | 77 | M | sAD |
| CENSOi058-A | E3/E3 | Not tested | N | 45 | F | Not affected at time of donation |
| CENSO-SS-i004-A | E3/E3 | Not tested | Y | 81 | M | Not affected at time of donation |
| CENSO-SS-i006-A | E3/E3 | Not tested | Y | 70 | M | Not affected at time of donation |
| CENSO-SS-i009-A | E3/E3 | Not tested | Y | 80 | M | sAD |
| CENSO-SS-i010-A | E3/E3 | Not tested | Y | 83 | M | sAD |
| CENSO-SS-i013-A | E3/E3 | Not tested | Y | 79 | F | sAD |
| CENSOi074-A | E3/E4 | Not tested | N | 60 | M | sAD |
| CENSOi077-C | E3/E4 | Not tested | N | 52 | F | sAD |
| CENSO-SS-i001-A | E3/E4 | High | Y | 70 | M | sAD |
| CENSO-SS-i002-A | E3/E4 | High | Y | 77 | M | sAD |
| CENSO-SS-i003-A | E3/E4 | High | Y | 72 | M | sAD |
| CENSO-SS-i011-A | E3/E4 | Not tested | Y | 74 | M | sAD |
| CENSO-SS-i013-A | E3/E4 | Not tested | Y | 82 | M | sAD |
| CENSO-SS-i013-A | E3/E4 | Not tested | Y | 72 | F | sAD |
| CENSO-SS-i008-A | E4/E4 | Not tested | Y | 69 | F | sAD |
| CENSO-SS-i012-A | E4/E4 | Not tested | Y | 76 | F | sAD |